{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:14:11Z","timestamp":1783430051156,"version":"3.54.6"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CMRPG3M1721"],"award-info":[{"award-number":["CMRPG3M1721"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CMRPG3M1691"],"award-info":[{"award-number":["CMRPG3M1691"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atezolizumab plus bevacizumab (Atezo\/Bev) is the standard first\u2010line therapy for unresectable hepatocellular carcinoma (uHCC). In the IMbrave150 trial, bevacizumab\u2010related adverse events (AEs) frequently required dose interruption or discontinuation, raising concerns regarding optimal dosing. The effect of initiating therapy with low\u2010dose bevacizumab remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analysed 307 uHCC patients who received Atezo\/Bev as first\u2010line therapy between 2020 and 2025. Patients were categorised into standard\u2010dose (15\u2009mg\/kg) or low\u2010dose (5\u20137.5\u2009mg\/kg) groups, with low\u2010dose allocation determined solely by a patient support programme, not by clinical discretion. After 1:1 propensity score matching, 122 patients in each group were compared. The primary endpoints were progression\u2010free survival (PFS) and overall survival (OS), and the secondary endpoints included objective response rate (ORR), disease control rate (DCR) and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Efficacy outcomes were similar between low\u2010 and standard\u2010dose groups: ORR (37.7% vs. 32.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.421), DCR (65.6% vs. 64.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.789), median PFS (7.3 vs. 8.1\u2009months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.460) and OS (24.6 vs. 20.7\u2009months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.689). The incidence of severe AEs did not differ, but low\u2010dose bevacizumab significantly reduced low\u2010grade toxicities, including proteinuria (28.7% vs. 40.2%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.045), rash (10.7% vs. 23.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007), thrombocytopenia (13.9% vs. 20.5%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.049) and gastrointestinal bleeding (1.6% vs. 4.9%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.044). Moreover, post\u2010progression overall survival did not significantly differ between prior standard\u2010 and low\u2010dose bevacizumab patients (11.2 vs. 9.4\u2009months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.700).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real\u2010world cohort, low\u2010dose bevacizumab preserved antitumor efficacy while reducing key AEs, suggesting that a dose de\u2010escalation strategy may improve tolerability without an early compromise in survival outcomes, although longer follow\u2010up is needed to confirm that long\u2010term efficacy remains comparable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/liv.70617","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T09:17:13Z","timestamp":1774689433000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Low\u2010Dose Bevacizumab Maintains Efficacy With Reduced Adverse Events in Liver Cancer"],"prefix":"10.1111","volume":"46","author":[{"given":"Po\u2010Ting","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology Chang Gung Memorial Hospital, Linkou Medical Center  Taoyuan Taiwan"},{"name":"College of Medicine Chang Gung University  Taoyuan Taiwan"},{"name":"Liver Research Center Chang Gung Memorial Hospital, Linkou Medical Center  Taoyuan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Chang Gung Memorial Hospital, Linkou Medical Center  Taoyuan Taiwan"},{"name":"College of Medicine Chang Gung University  Taoyuan Taiwan"},{"name":"Liver Research Center Chang Gung Memorial Hospital, Linkou Medical Center  Taoyuan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi\u2010Chung","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Chang Gung Memorial Hospital, Linkou Medical Center  Taoyuan Taiwan"},{"name":"College of Medicine Chang Gung University  Taoyuan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung\u2010Han","family":"Wu","sequence":"additional","affiliation":[{"name":"College of Medicine Chang Gung University  Taoyuan Taiwan"},{"name":"Department of Surgery Chang Gung Memorial Hospital, Linkou Medical Center  Taoyuan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei\u2010Ting","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Chang Gung Memorial Hospital, Linkou Medical Center  Taoyuan Taiwan"},{"name":"College of Medicine Chang Gung University  Taoyuan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen\u2010Chun","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Chang Gung Memorial Hospital, Linkou Medical Center  Taoyuan Taiwan"},{"name":"Department of Gastroenterology and Hepatology New Taipei Municipal City Tucheng Hospital  New Taipei City Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi\u2010Ming","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Chang Gung Memorial Hospital, Linkou Medical Center  Taoyuan Taiwan"},{"name":"College of Medicine Chang Gung University  Taoyuan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun\u2010Yen","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Chang Gung Memorial Hospital, Linkou Medical Center  Taoyuan Taiwan"},{"name":"College of Medicine Chang Gung University  Taoyuan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000537686"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000466"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.08.028"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10732-z"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000535501"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2022.09.005"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00908-7"},{"issue":"4","key":"e_1_2_13_10_1","first-page":"265","article-title":"Dose\u2010Reduction of Bevacizumab in Atezolizumab Plus Bevacizumab Therapy Extends Treatment Duration With Disease Control in Patients With Hepatocellular Carcinoma","volume":"103","author":"Sakai M.","year":"2025","journal-title":"Oncology"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000544981"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.01.012"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.843"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.727102"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm988"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv197"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0835"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1989"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215397109"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1710754114"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI93182"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00978"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00426"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.70617","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.70617","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.70617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:17:10Z","timestamp":1783426630000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.70617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/liv.70617"],"URL":"https:\/\/doi.org\/10.1111\/liv.70617","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"2025-12-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70617"}}